Feed CNGGF
Summary
41 / 100 · Bulios Score
Valuation 100Growth 0Profitability 20Quality 47Debt 44Stability 30
What speaks for it
- Out of every 100 AUD of revenue, 237 AUD is left as net profit.
- You pay 0.2 AUD for 1 AUD of yearly profit, little for its sector.
What to watch
- Revenue fell by 25% a year over the last 3 years.
- It reports a profit, yet spends more cash than it brings in.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapDrug Manufacturers - Specialty & Generic industry median
P/E today 0.2
Today you pay 0.2 AUD for 1 AUD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (AUD)
20222023202420252026
Diluted EPS (AUD)
20222023202420252026
Revenue fell by 0.0% a year over 5 years. Over the last 3 years it fell by 25% a year.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Cash and short-term investments $489.3K
Debt $16.8M
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.